Hmmm... seems a cheap initial buy in to me but a good deal if...

Hmmm... seems a cheap initial buy in to me but a good deal if the milestone payments aren't too many years away!

We have to wait for commercialisation to receive the larger deal value of 'mid-teens royalty', and I would think that is a nice repeating revenue stream. This was a similar structure to Cantrixil!?

Makes me think our board are looking at a future strategy that involves drug develop with a revenue stream that will allow ongoing development opportunities with minimal to no capital raisings?

I particularly like their QnA and the 8-10% market share this ONLY represents!!!